A further analysis of the transcriptional profiles in glomeruli purified from the rat groups revealed that the MRS1754 treatment strongly affected the expression of several inflammation-related genes associated with the progression of DN, including the IL1β and NLRP3 components of the inflammasome, chemokines, complement factors and receptors, and gremlin (Figure 4B). The gene discussed is GREM1; the disease is liver dysplastic nodule.